In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei

Objectives Penicillium marneffei infection is an important disease among human immunodeficiency virus patients in south-east Asia, including southern China. However, therapeutic strategies are limited. Combination regimens with synergistic drugs could provide additional options for treating penicill...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2009-02, Vol.63 (2), p.340-342
Main Authors: Cao, Cunwei, Liu, Wei, Li, Ruoyu, Wan, Zhe, Qiao, Jianjun
Format: Article
Language:English
Subjects:
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antifungal Agents - pharmacology
antifungal susceptibility
Antimicrobial agents
Biological and medical sciences
Cell culture
combined therapy
dimorphic fungi
Drug Interactions
Drug therapy
Fungal infections
Human immunodeficiency virus
Humans
Medical sciences
Microbial Sensitivity Tests
Penicillium - drug effects
Penicillium marneffei
Pharmacology
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives Penicillium marneffei infection is an important disease among human immunodeficiency virus patients in south-east Asia, including southern China. However, therapeutic strategies are limited. Combination regimens with synergistic drugs could provide additional options for treating penicilliosis. We evaluated the in vitro efficacy of combining micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic yeast form of P. marneffei. Methods Twenty isolates of P. marneffei were assayed. Drug interactions were assessed with the chequerboard technique using the CLSI (formerly the NCCLS) microdilution method (M27-A2) with minor modifications. The fractional inhibitory concentration index (FICI) was used to classify drug interactions. Results were interpreted as follows: synergy, FICI ≤0.5; no interaction, FICI >0.5 and ≤4.0; or antagonism, FICI >4.0. Results The in vitro interactions of micafungin combined with itraconazole showed the highest percentage of synergic interaction (65%); for the micafungin/amphotericin B combination, 50% of the isolates had synergic interaction. Micafungin significantly enhanced the antifungal activity of amphotericin B and itraconazole against P. marneffei. Micafungin, however, did not enhance the activity of fluconazole and no synergism was observed with this combination. Antagonism was not detected for any of the antifungal combinations assayed. Conclusions The results of this study suggest that micafungin enhances the efficacy of itraconazole or amphotericin B in vitro and indicate that an echinocandin, such as micafungin, might have a potential role in combination therapy among patients infected with P. marneffei.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkn494